Back to Market Feed

Product Information

QELBREE ER 150 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $12.7339 per EA under NDC 17772013230. Its NADAC has been published 235 times since Feb 23, 2022.

FDA first approved this application on Apr 2, 2021.

QELBREE ER 150 MG CAPSULE

viloxazine hydrochloride
$12.7339per EA

Strength

150 mg/1

NDC

17772013230

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

VILOXAZINE HYDROCHLORIDE

Approval Type

New Drug (NDA)

FDA Application

NDA211964

FDA Approved

4/2/2021

On Market Since

4/2/2021

Pharmacological Classes

Cytochrome P450 1A2 Inhibitors
Cytochrome P450 2B6 Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Norepinephrine Reuptake Inhibitor
Norepinephrine Uptake Inhibitors

Price Statistics

The NADAC for QELBREE ER 150 MG CAPSULE has been published 235 times since Feb 23, 2022, and over the history we have for it it has risen 25.9%. The table below summarizes its recorded NADAC range and movement.

Current price$12.7339 per EA
All-time high$12.7546 (Jun 10, 2026)
All-time low$10.1146 (Feb 23, 2022)
52-week high$12.7546
52-week low$12.0140
Median price$11.3700
Average price$11.3273
Largest weekly change+6.0% (Jan 3, 2024)
Weeks tracked235
Tracking sinceFeb 23, 2022

Price History

1W

-0.0%

1M

-0.0%

3M

-0.2%

6M

-0.1%

1Y

+5.8%

3Y

+18.8%

5Y

N/A

All

+25.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the viloxazine hydrochloride market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

TIAZAC ER 180 MG CAPSULE
Brand
00187261330•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 180 MG CAPSULE
Brand
00187261390•Bausch Health US LLC
$1.5060
per EA
MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2069
per ML
TIAZAC ER 360 MG CAPSULE
Brand
00187261630•Bausch Health US LLC
$2.7628
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261690•Bausch Health US LLC
$2.7628
per EA
NEORAL 25 MG GELATIN CAPSULE
Brand
00078024615•Novartis Pharmaceuticals Corporation
$2.9457
per EA
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
CARDIZEM LA 120 MG TABLET
Brand
00187204530•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 120 MG TABLET
Brand
00187204590•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 180 MG TABLET
Brand
00187204630•Bausch Health US LLC
$3.8314
per EA

Frequently asked questions

What is the NADAC price of QELBREE ER 150 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for QELBREE ER 150 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $12.7339 per EA (NDC 17772013230), effective Aug 19, 2026.

How has the price of QELBREE ER 150 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for QELBREE ER 150 MG CAPSULE has risen 25.9%. It has been tracked across 235 weekly CMS publications since Feb 23, 2022.

What are the highest and lowest recorded NADAC prices for QELBREE ER 150 MG CAPSULE?

Since Feb 23, 2022, the NADAC for QELBREE ER 150 MG CAPSULE has ranged from a low of $10.1146 (Feb 23, 2022) to a high of $12.7546 (Jun 10, 2026), with a median of $11.3700 per EA.

Are there cheaper alternatives to QELBREE ER 150 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of QELBREE ER 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures QELBREE ER 150 MG CAPSULE?

QELBREE ER 150 MG CAPSULE (NDC 17772013230) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.